Scarica l'app Stockscreener
47.91
5.00%
-2.52
Dopo l'orario di chiusura:
47.67
-0.24
-0.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$50.43
Aprire:
$51.23
Volume 24 ore:
2.66M
Relative Volume:
1.25
Capitalizzazione di mercato:
$4.11B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-17.11
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
-3.64%
1M Prestazione:
+15.42%
6M Prestazione:
-4.16%
1 anno Prestazione:
-41.86%
Intervallo 1D:
$47.34
$51.47
Intervallo di 1 settimana:
$47.34
$55.88
Portata 52W:
$36.52
$91.10
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
47.91 | 4.11B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 3.4%Here's Why - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 18,360 Shares - MarketBeat
Crispr therapeutics CEO sells $1.01 million in stock - Investing.com India
CRISPR Therapeutics AG CEO Samarth Kulkarni Sells Shares - TradingView
Stock Traders Purchase High Volume of CRISPR Therapeutics Call Options (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 2%What's Next? - MarketBeat
Cantor Fitzgerald Has Weak Outlook for CRSP FY2025 Earnings - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Lifted by Allworth Financial LP - MarketBeat
Crispr therapeutics COO Bruno Julianne sells $17,582 in stock By Investing.com - Investing.com South Africa
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpShould You Buy? - MarketBeat
CRISPR set to snap six days of gains as shares trade in red - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 4.1%Time to Sell? - MarketBeat
Market Whales and Their Recent Bets on CRSP Options - Benzinga
CRISPR Therapeutics: Navigating a Genetic Revolution Amid Healthcare Challenges - Reporteros del Sur -
CRISPR Therapeutics AG (CRSP): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq
Van ECK Associates Corp Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics' general counsel sells shares worth $619,492 By Investing.com - Investing.com Australia
Crispr Therapeutics' general counsel sells shares worth $619,492 - Investing.com India
Crispr therapeutics COO Bruno Julianne sells $17,582 in stock - Investing.com
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
CRISPR Therapeutics (CRSP) Projected to Post Earnings on Wednesday - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 3.4%Here's Why - MarketBeat
Cantor Fitzgerald Reiterates "Neutral" Rating for CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) Target Price at $74.50 - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Given New $82.00 Price Target at Citigroup - MarketBeat
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year - Investing.com Australia
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year By Investing.com - Investing.com South Africa
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell? - Nasdaq
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Morgan Stanley Forecasts Strong Price Appreciation for CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by Evercore ISI to Outperform Rating - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Outperform at Evercore ISI - MarketBeat
Research Analysts Offer Predictions for CRSP Q1 Earnings - MarketBeat
CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last? - MSN
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? - Benzinga
Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US - GlobeNewswire Inc.
CRISPR Therapeutics (NASDAQ:CRSP) Given New $120.00 Price Target at Truist Financial - MarketBeat
Q1 Earnings Forecast for CRSP Issued By Leerink Partnrs - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Sell at StockNews.com - MarketBeat
Stifel Nicolaus Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $49.00 - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
CRISPR Therapeutics (CRSP): Tailored Genetic Engineering - Securities.io
How to Take Advantage of moves in (CRSP) - Stock Traders Daily
Evercore ISI Group Upgrades CRISPR Therapeutics (LSE:0VRQ) - Nasdaq
Capital Advisors Inc. OK Buys 9,681 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
BRIEF-Crispr Therapeutics AG shares open at $15 in debut, above IPO price of $14/shr - Wealth Management
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $32.00 at Morgan Stanley - MarketBeat
Stifel cuts CRISPR Therapeutics target to $49, holds rating - MSN
Why CRISPR Therapeutics (CRSP) Soared on Friday? - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap Up Following Strong Earnings - MarketBeat
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):